Sirona Biochem Corp V.SBM

The last was my conclusion

[Geheimnisvoller]

- Sirona's synthetic chemists have learned how to strengthen the bond of a carbohydrate molecule by strategically placing fluorine atoms within the molecule....
https://www.sironabiochem.com/programs/proprietary-platform-technology/

My conclusion:
Such carbohydrate molecules are used by various viral agents to bond to the cells. If this is no longer possible, the virus cannot use the replication mechanism of the cells

_____________________________

Antiviraler Tweet - Chance for Sirona
https://twitter.com/i/topics/news/e638521389?

cn=ZmxleGlibGVfcmVjcw%3D%3D&refsrc=https://www.scientificamerican.com/article/there-are-few-goo…

This could be a very big chance fr Sirona Biochem ...

-Two of the current best available treatments, monoclonal antibodies and the drug remdesivir, are given by infusion. Patients only benefit during the first week or so of infection, when the virus is still present and replicating in the body. These medications are expensive and often unavailable outside of large teaching hospitals. In many instances, patients are treated too late, after the disease has already shifted to a more dangerous hyperinflammatory state.

-Biden administration announced in June that it would spend more than $3 billion on a program aimed at developing next-generation antiviral therapies—not just for COVID but also for other viruses that pose a future threat.

- The goal of an antiviral pill is to stop the pathogen from replicating, but finding drugs that can do that without injuring the infected human cell is no easy task. Scientists start by screening thousands of compounds for their efficacy in targeting SARS-CoV-2 in cell culture. Promising candidates are then tested in animals—both to ensure that the drugs are not toxic and that they are not immediately destroyed in the body and reach tissues in the lungs and other organs in sufficient amounts.

-Rachel Bender Ignacio, a physician-scientist at the Fred Hutchinson Cancer Research Center in Seattle, anticipates that the virus will develop less resistance against direct-acting small-molecule drugs such as molnupiravir than it has against monoclonal antibodies.

-Molnupiravir, which is in a class of drugs called nucleoside analogues, works by inserting itself into a newly forming viral RNA strand. The strand will then stop growing or become so heavily mutated that replication cannot continue. Scientists say molnupiravir and other direct-acting agents can also be combined in therapeutic cocktails, mirroring how drugs for viral diseases such as HIV and hepatitis C are given today. “You’re looking for drugs with different and complimentary mechanisms of action,” Sheahan says.